Suppr超能文献

评估氨甲环酸在小儿颅骨重建术中应用的安全性和有效性。

Evaluating the safety and efficacy of tranexamic acid administration in pediatric cranial vault reconstruction.

作者信息

Crantford John Clayton, Wood Benjamin C, Claiborne Jeffrey R, Ririe Doug G, Couture Daniel E, Thompson James T, David Lisa R

机构信息

From the Departments of *Plastic and Reconstructive Surgery, †Anesthesiology, and ‡Neurosurgery, Wake Forest Baptist Medical Center, Winston-Salem, North Carolina.

出版信息

J Craniofac Surg. 2015 Jan;26(1):104-7. doi: 10.1097/SCS.0000000000001271.

Abstract

BACKGROUND

Blood loss is the leading cause of mortality after major craniofacial surgery. Autologous blood donation, short-term normovolemic hemodilution, and intraoperative blood salvage have shown low efficacy in decreasing transfusions. Tranexamic acid (TXA) is a synthetic antifibrinolytic drug that competitively decreases the conversion of plasminogen to plasmin, thereby suppressing fibrinolysis. The purpose of this study was to investigate the impact that TXA administration has on intraoperative blood loss and blood product transfusion in pediatric patients undergoing cranial vault reconstruction.

METHODS

An Internal Review Board-approved retrospective study was conducted on a consecutive series of pediatric patients undergoing cranial vault reconstruction from January 2009 to June 2012. Seventeen consecutive patients who received TXA at the time of cranial vault reconstruction were compared with 20 patients who did not receive TXA. Criteria for blood product transfusion were identical for both groups. Outcomes including perioperative blood loss, volume of blood transfused, and adverse effects were analyzed.

RESULTS

The TXA group had a significantly lower perioperative blood loss (9.4 versus 21.1 mL/kg, P < 0.0001) and lower volume of perioperative mean blood product transfusion (12.8 versus 31.3 mL/kg, P < 0.0001) compared with the non-TXA group. There was no significant difference in demographic data, infection rate, change in preoperative to postoperative hematocrit, duration of surgery, or complication rates between the TXA and non-TXA groups. No drug-related adverse effects were identified in patients who received TXA.

CONCLUSIONS

The use of TXA in pediatric cranial vault reconstruction significantly reduces perioperative blood loss and blood product transfusion requirements. The TXA administration is safe and may improve patient outcomes by decreasing the likelihood of adverse effects related to blood product transfusion.

摘要

背景

失血是大型颅面外科手术后死亡的主要原因。自体输血、短期等容血液稀释和术中血液回收在减少输血方面效果不佳。氨甲环酸(TXA)是一种合成抗纤溶药物,可竞争性减少纤溶酶原向纤溶酶的转化,从而抑制纤维蛋白溶解。本研究的目的是调查在接受颅盖重建的儿科患者中使用氨甲环酸对术中失血和血液制品输注的影响。

方法

对2009年1月至2012年6月连续接受颅盖重建的儿科患者进行了一项经内部审查委员会批准的回顾性研究。将17例在颅盖重建时接受氨甲环酸的连续患者与20例未接受氨甲环酸的患者进行比较。两组血液制品输注标准相同。分析围手术期失血、输血量和不良反应等结果。

结果

与未使用氨甲环酸组相比,氨甲环酸组围手术期失血量显著更低(9.4 对比 21.1 mL/kg,P < 0.0001),围手术期平均血液制品输血量也更低(12.8 对比 31.3 mL/kg,P < 0.0001)。氨甲环酸组和未使用氨甲环酸组在人口统计学数据、感染率、术前至术后血细胞比容变化、手术持续时间或并发症发生率方面无显著差异。接受氨甲环酸的患者未发现与药物相关的不良反应。

结论

在儿科颅盖重建中使用氨甲环酸可显著减少围手术期失血和血液制品输注需求。使用氨甲环酸是安全的,并且通过降低与血液制品输注相关不良反应的可能性可能改善患者预后。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验